Form 8-K IRONWOOD PHARMACEUTICALS For: Feb 18
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
BTIG Sees Opportunity in Ironwood Pharma (IRWD) Weakness; Affirms at 'Buy'
February 19, 2016 7:50 AM ESTBTIG affirms its Buy rating and $15 price target on Ironwood Pharmaceuticals (Nasdaq: IRWD) following IRWD's Q4 results issued Thursday night.
Analyst Timothy Chiang noted that IRWD's Q4 included $53.3 million of collaboration revenue (vs. our $44 million estimate) and a loss per share of... More
